NCT05546723View on ClinicalTrials.gov

LMY-920 for Treatment of Relapsed or Refractory Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 13, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

October 31, 2025

Conditions
Multiple Myeloma, RefractoryMultiple Myeloma in Relapse
Interventions
BIOLOGICAL

Autologous CAR-T cell therapy expressing the BAFF-ligand.

LMY-920

Trial Locations (1)

44106

RECRUITING

University Hospitals Seidman Cancer Center, Cleveland

Sponsors
All Listed Sponsors
collaborator

The Cleveland Clinic

OTHER

collaborator

Case Western Reserve University

OTHER

lead

Luminary Therapeutics

INDUSTRY